Entera Bio Ltd.
ENTXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
3dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
ENTX Earnings Report
EPS Est: $-0.08 | FQ end 2026-06
How ENTX's past catalysts played out
EB612 (EBP05)
Hypoparathyroidism
EBP05
Hypoparathyroidism
EnteraBio's Oral Parathyroid Hormone (1-34)
Hypoparathyroidism
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EB612 (EBP05) | Phase 2 | Hypoparathyroidism | - | - |
EBP05 | Phase 2 | Hypoparathyroidism | - | - |
EnteraBio's Oral Parathyroid Hormone (1-34) | Phase 2 | Hypoparathyroidism | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Entera Bio Ltd.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Entera Bio Ltd.'s (ENTX) pipeline across Phase 2. Its lead program is EB612 (EBP05) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entera Bio Ltd.'s next FDA catalyst?→
Entera Bio Ltd.'s (ENTX) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENTX biotech catalysts?→
Add ENTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entera Bio Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.